ARCA Biopharma is a late-stage biopharmaceutical company based in Denver, CO, specializing in tailored healthcare and pharmacogenetic precision medicine for cardiovascular disease, particularly atrial fibrillation. They aim to address the unmet medical need for safe and effective drug therapies for patients with atrial fibrillation and heart failure, utilizing their potentially groundbreaking genetically-targeted AF treatment, Gencaro.
With a focus on precision medicine, ARCA Biopharma is dedicated to tailoring medical treatment to the individual characteristics of each patient. They recognize the significant impact of cardiovascular disease, the leading cause of death in the United States, and strive to develop innovative solutions to improve patient outcomes and reduce the burden on the healthcare system.
Generated from the website